Pfizer Inc.
@pfizer_news
Followers
33,982
Following
794
Media
257
Statuses
1,078
The official Twitter channel dedicated to media announcements & investor communications from Pfizer Inc. To see all of our Tweets, please follow @pfizer .
New York
Joined March 2012
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
FEMA
• 1184615 Tweets
Tina Peters
• 196715 Tweets
Porto
• 112943 Tweets
Manchester United
• 107645 Tweets
Beşiktaş
• 102706 Tweets
Ten Hag
• 96383 Tweets
The Boss
• 91923 Tweets
Liz Cheney
• 90520 Tweets
Martinez
• 88455 Tweets
Avrupa
• 74552 Tweets
#okanburukistifa
• 71750 Tweets
#GHGala5
• 61647 Tweets
Hoca
• 54122 Tweets
Evans
• 52248 Tweets
#grandefratello
• 47820 Tweets
Rashford
• 43839 Tweets
Maguire
• 40947 Tweets
Samu
• 34804 Tweets
EL DESTELLO IS OUT
• 32138 Tweets
Mert
• 26798 Tweets
Violeta
• 26456 Tweets
Bruce Springsteen
• 23909 Tweets
Bruno Fernandes
• 23014 Tweets
天使の日
• 19483 Tweets
Onana
• 18517 Tweets
De Ligt
• 17554 Tweets
Dalot
• 14814 Tweets
Maite
• 14714 Tweets
#PORMUN
• 14682 Tweets
Ersin
• 14407 Tweets
もちづきさん
• 14282 Tweets
Muçi
• 13822 Tweets
szymanski
• 13776 Tweets
Garnacho
• 11868 Tweets
Hashem Safieddine
• 11495 Tweets
ゴールデン進出
• 10598 Tweets
Today along with
@biontech_group
, we announced the signing of a letter of intent with
@biovac_inst
, a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union:
8
65
162
Thomson Reuters CEO James C. Smith elected to Pfizer Board of Directors
http://t.co/ZeZkq36ida
69
117
135
In order to realize the breakthroughs of the future, we’ve revolutionized how we work today. We're unlocking the pill to reveal Pfizer’s DNA: the power of science.
479
42
99
UPDATE: Earlier today, we announced preliminary data from our ongoing Phase 1/2 study with
@BioNTech_Group
for a SARS-CoV-2 mRNA-based
#vaccine
candidate: $PFE
#COVID19
3
52
79
Today, we announced the start of a Phase 3 clinical study investigating our
#Lymedisease
vaccine candidate, being developed in partnership with
@ValnevaSE
.
Learn more about our research:
10
24
78
Together with
@ValnevaSE
, we announced positive data on the use of our
#Lyme
disease vaccine candidate in children aged 5-17 years. Read more:
7
11
54
Today with
@valnevaSE
, we are excited to announce additional positive Phase 2 results, including booster response, for our Lyme disease
#vaccine
candidate.
5
14
50
Today, along with
@BioNTech_Group
, we shared positive early data on our lead mRNA-based
#vaccine
candidate (BNT162b2) against
#COVID19
: $PFE $BNTX
1
7
35
Today we entered into a definitive merger agreement under which we will acquire
@ArrayBioPharma
. Read More:
2
24
36
4
17
38
BREAKING: Today, with
@BioNTech_Group
, we submitted a request to US FDA to expand emergency use of our COVID-19 vaccine to adolescents 12 to 15 years of age.
6
9
29
Today, with
@BioNTech_Group
, we released results from an in vitro study indicating sera from people immunized with the Pfizer-BioNTech
#COVID19
vaccine can neutralize the SARS-CoV-2 U.K. strain. Learn more:
5
13
35
Today with
@BioNTech_Group
, we are proud to announce positive topline results from the pivotal trial of our
#COVID19
vaccine in children 5-11 years of age.
8
19
35
Today with
@BioNTech_Group
, we’re proud to announce that results from the Phase 2/3 study for the Pfizer-BioNTech
#COVID19
Vaccine in children 5 through 11 years of age were published in The New England Journal of Medicine (
@NEJM
).
58
11
31
Together with
@ValnevaSE
, we are pleased to announce encouraging antibody persistence data six months after the last dose of our
#Lymedisease
vaccine candidate in development for adults and children aged 5-65.
Learn more about our research:
18
10
31
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
2
11
29
Updated Phase 1/2 data for our investigational
#hemophilia
A treatment in partnership with
@SangamoTx
were presented today at
#ASH19
. ICYMI:
#raredisease
2
13
30
Today with
@BioNTech_Group
, we announced plans to expand our agreement with the U.S. government to provide 500 million more doses of our
#COVID19
vaccine to be distributed to countries around the world.
Learn more:
2
9
33
BREAKING: Today our
#COVID19
vaccine with
@BioNTech_Group
was granted full approval by
@US_FDA
for those 16+.
8
12
35
Today, the
@US_FDA
approved our once-daily oral treatment for adults with refractory moderate-to-severe
#atopicdermatitis
who have not responded to other systemic treatments or for whom these treatments are inadvisable. Learn more:
9
5
32
We are pleased to share the publication of two studies related to our investigational vaccine for the prevention of respiratory syncytial virus (RSV), in The Journal of Infectious Diseases:
10
9
31
BREAKING:
@US_FDA
granted emergency use authorization of a booster dose of our
#COVID19
vaccine w
@BioNTech_Group
for individuals 65+, and 18+ through 64 within certain high risk groups. This is the first FDA EUA of a COVID-19 vaccine booster.
Learn more:
9
2
30
0
16
24
BREAKING: The Conditional Marketing Authorization in the EU for the Pfizer-BioNTech
#COVID19
vaccine has been expanded to include adolescents 12 to 15 years old.
5
9
30
We are pleased to share the
@US_FDA
and
@EMA_News
have accepted the filing applications for our investigational bispecific antibody treatment for people living with relapsed or refractory multiple myeloma (
#RRMM
). Learn more:
#MultipleMyeloma
#MMSM
22
8
27
Today, we announced preliminary preclinical data with
@BioNTech_Group
for BNT162b2, our mRNA-based
#vaccine
candidate against
#COVID19
: $PFE $BNTX
6
11
28
Building on our leadership in
#breastcancer
innovation, today we announced a global collaboration w/
@ArvinasInc
to develop a novel PROTAC® Protein Degrader. Learn more here:
0
11
27
BREAKING: The
@US_FDA
has approved our combination therapy for the treatment of metastatic castration-resistant
#ProstateCancer
(mCRPC) in adults with homologous recombination repair (HRR) gene mutations:
1
12
27
Our work continues and in just a few weeks, we will share new data on our medicines at the first ever virtual ASCO meeting. Learn more about our oncology portfolio
#ASCO20
:
1
3
26
Announced today: positive topline results from our Phase 3 trial in advanced
#prostatecancer
. We are proud to take this step toward potentially addressing unmet needs among this population.
9
11
26
Results from an in vitro study show sera from clinical trial participants who received the Pfizer-BioNTech COVID-19 vaccine effectively neutralized SARS-CoV-2 having 1 key mutation also found in 2 highly transmissible strains. Learn more:
3
9
24
Today, with
@BioNTech_Group
, we announced positive topline results in adolescents 12-15 years of age from the Phase 3 Pfizer-BioNTech
#COVID19
vaccine study.
6
5
24
Pfizer announces CEO succession plan: Dr. Albert Bourla to succeed Ian Read as CEO, effective January 1, 2019 $PFE
0
9
25
We're pleased to announce that our investigational treatment for relapsed or refractory
#multiplemyeloma
was granted U.S. FDA Breakthrough Therapy Designation. MM is an aggressive blood cancer with limited treatment options for these patients. Learn more:
13
7
20
Today we announced positive top-line results from a Phase 3 study of our investigational treatment for patients 12 and older with moderate to severe atopic
#dermatitis
:
1
5
20
Today, along with
@BioNTech_Group
we announced the signing of a letter of intent with Brazil biopharmaceutical company
@Eurofarma
to manufacture the Pfizer-BioNTech COVID19 Vaccine for distribution across Latin America:
6
6
25
We’re pleased to share that the European Commission has approved our
#oncology
supportive care
#biosimilar
in people living with certain types of
#cancer
. Find out more:
0
3
18
Today, we announced positive top-line data from a Phase 3 study evaluating our investigational gene therapy for the treatment of adult males with moderately severe to severe
#hemophiliaB
.
Learn more about the study here:
63
6
21
Today we announced the acquisition of
@biohaven
, the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. Read the announcement press release:
8
6
21
The
@US_FDA
has accepted for review two NDAs for our investigational treatment for transthyretin amyloid cardiomyopathy, a
#raredisease
that affects the heart. Learn more:
1
8
17
As SARS-CoV-2 continues to evolve, we are working w/
@BioNTech_Group
to understand potential long-term immunity afforded by our vaccine, whether there will be a need for booster shots, and any threat to protection by our vaccine from circulating or new variants of concern.
10
10
21
Updated topline analysis of 927 confirmed symptomatic cases of
#COVID19
from the landmark Pfizer-BioNTech COVID-19 vaccine study showed high efficacy and favorable safety profile of the vaccine.
3
3
19
The
@US_FDA
has granted Fast Track designation for our investigational
#genetherapy
for the treatment of
#Duchenne
muscular dystrophy, signifying an important milestone for this community. Learn more:
0
7
21
We’re pleased to share that the U.S. FDA has approved our first-line treatment for patients with metastatic
#NSCLC
with certain EGFR-activating mutations.
0
9
18
Following an extensive discussion with President Trump, Ian Read announced that it will defer the company’s July 1 price increases to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients.
7
9
18
Today, with
@BioNTech_Group
, we announced results from an in vitro study published in
@NEJM
examining whether sera from individuals vaccinated with our
#COVID19
vaccine neutralized SARS-CoV-2 with the South African variant spike protein. Learn more:
2
6
18
Today, we announced the start of a Phase 3 trial evaluating our investigational vaccine candidate against respiratory syncytial virus (
#RSV
) in adults ages 60 years or older.
3
9
20
We received FDA Fast Track designation w/
@LillyPad
for investigational non-opioid therapy for 2
#chronicpain
types
0
7
18
We’re proud to announce that the US FDA has accepted our sNDA filing and granted Priority Review for our advanced
#prostatecancer
therapy. Read more:
0
2
17
We’re pleased to announce an expanded collaboration with
@flatironhealth
as we continue our pursuit to unlock the power of
#realworldevidence
in
#oncology
to improve medicines development.
1
8
18
Pfizer To Build Cutting-Edge Sterile Injectable Facility In Michigan, Investing Nearly Half A Billion Dollars In U.S. Manufacturing, Creating More Than 450 Jobs
5
11
13
Today, with
@BioNTech_Group
, we announced results from an in vitro study conducted with
@utmbhealth
demonstrating sera from individuals vaccinated with our
#COVID19
vaccine:
5
8
19
Today, the FDA approved our breakthrough therapy for relapsed/refractory Acute Lymphoblastic
#Leukemia
in adults
0
10
15
Sharing progress on the most recent research and development activities that reinforce the dedication behind our five-point plan to battle the
#COVID19
pandemic:
0
5
20
Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an investigational oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
0
3
12
We are proudly continuing our commitment to the
#Duchenne
muscular dystrophy community. Today, we announced the first participant was dosed in our Phase 3 investigational gene therapy trial for affected boys aged 4-7.
1
6
16
Today, we announced the initiation of four Phase 3 studies within our current pipeline of investigational vaccines. Learn more about the vaccine candidates:
0
5
15
Today, Pfizer pledged $100 million to the AMR Action Fund, a collaboration between more than 20 biopharma companies to help reinvigorate the antibiotic pipeline and fight
#antimicrobialresistance
. Get all the details:
1
3
14
We are proud to announce that the
@US_FDA
has approved our treatment regimen for adults living with BRAF V600E-mutant metastatic
#colorectalcancer
who have received prior therapy. Learn more:
1
2
17
NEWS:
@US_FDA
grants approval of a vaccine to help protect against pneumococcal disease in adults 18 years and older. More:
4
8
18
As we continue to be led by the science, today we are providing an update on our comprehensive
#COVID19
vaccine booster strategy in light of emerging data including data relating to the
#DeltaVariant
.
4
5
16
To further expand our commitment to
#infectiousdisease
, we announced an agreement under which Pfizer has acquired Amplyx Pharmacueticals, Inc. Learn more about this news & hear from Angela Lukin:
1
1
16
We’re excited to announce positive Phase 2 data in alopecia areata presented as a late-breaker at
#EADV2018
. Learn more:
0
5
14
NEWS: Pfizer has finalized an investment in
@Spero_Tx
– including terms on a potential medicine to treat multi-drug resistant infections in the hospital setting
3
6
15
Today we entered a collaboration with
@Myovant
in the U.S. and Canada, with the goal of advancing care in
#oncology
and
#womenshealth
. Learn more:
4
7
17
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by FDA but has been authorized for emergency use to prevent COVID-19 in ages 12+. See Fact Sheet:
5
12
17
FDA grants Pfizer Breakthrough Therapy Designation for a next-generation vaccine intended to help prevent pneumococcal disease in adults aged 18 years and older. Learn more:
0
6
15
We continuously innovate to bring treatments to underserved patient populations. Today, the
@US_FDA
approved an expanded indication for our medicine for a certain type of
#metastaticBC
to include the treatment of men based predominately on
#realworlddata
.
0
7
12
Today, we announced positive top-line data from a Phase 3 trial of our bivalent respiratory syncytial virus vaccine candidate (
#RSVpreF
) in older adults, bringing us one step closer to helping address the substantial burden of RSV disease.
10
5
16
Today with
@BioNTech_Group
, we announced the first results from any randomized, controlled
#COVID19
vaccine booster trial. We look forward to sharing these data with regulatory agencies and submitting them for peer-reviewed publication.
6
6
17
The 2020
#PrixGalien
USA Award is a testament to
@ScrippsResearch
professors Jeffery Kelly, PhD, and Evan Powers, PhD who helped develop our innovative treatment for ATTR-CM.
#PfizerProud
5
2
15
Today’s FDA approval marks an exciting breakthrough for young patients with ALK-positive
#ALCL
& addresses a significant unmet need in
#bloodcancer
. Learn more:
0
2
14
In collaboration with
@SangamoTx
, we’re proud to announce that the first participant was dosed in a phase 3 investigational gene therapy trial for patients with
#hemophilia
A. Learn more about the trial and our gene therapy efforts:
2
3
17
UPDATE: We have completed the transaction to combine our Upjohn business with
@MylanNews
to form
@ViatrisInc
:
$PFE $MYL $VTRS
1
5
14
Today, the
@US_FDA
granted Breakthrough Therapy Designation for our vaccine to help prevent meningococcal group B disease in children ages 1-9. Read more:
4
3
13
The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the FDA but has been authorized for emergency use to prevent COVID-19 in ages 12+. See Fact Sheet:
3
8
14
We’re proud to announce that a new treatment for certain patients with the most common type of hereditary
#breastcancer
has been approved by the FDA $PFE
0
8
15
The FDA granted Breakthrough Therapy designation for our investigational treatment for alopecia areata. Learn more:
2
7
12
We’re pleased to present long-term data from our Phase 3 ALK-inhibitor CROWN study to treat
#lungcancer
at
#AACR22
.
5
6
12
0
5
13
Announced today: positive results from the Phase 3 trial of our
#RSV
maternal vaccine candidate. These data have shown that this vaccine candidate can help protect newborns against severe RSV-related respiratory illness immediately at birth. Learn more:
18
3
16
We’re proud to announce that the
@US_FDA
has approved our advanced
#prostatecancer
therapy to treat men with metastatic castration-sensitive prostate cancer. Learn more:
0
2
14